From bench to body: In vivo CAR engineering in the clinic.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41260204.
- Also identified by DOI 10.1016/j.xcrm.2025.102337 and PMC identifier 12711657.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In vivo CAR engineering is an emerging therapeutic platform for cancer and autoimmune diseases. Enabled by advanced delivery systems such as immune-evasive lentiviral vectors and targeted lipid nanoparticles, this strategy has progressed to early clinical testing, showing initial safety and efficacy. Here, key opportunities and translational hurdles are critically discussed.
Medical subject headings
- Receptors, Chimeric Antigen
- Neoplasms
- Immunotherapy, Adoptive